Right place, right time

e-Therapeutics offers public market investors a unique opportunity to gain exposure to a proprietary, cutting-edge in silico drug discovery platform that has already attracted significant investment and has been fully operational since 2014. This second-generation platform has generated new chemical entities (NCEs) in several different disease areas and, under a new CEO, is on the cusp of commercial validation. The priority for the company is securing deals to provide external validation of this approach. e-Therapeutics’ strength is its discovery capability, particularly in complex disease; it also has six internal discovery projects with the prospect of more to come. The CEO’s business review will determine the focus of internal investment and business development activities.